Company Overview - Alnylam Pharmaceuticals (ALNY) shares increased by 6% to close at $482.13, with notable trading volume compared to typical sessions, and a 4.6% gain over the past four weeks [1] Product Performance - The stock price gain is linked to positive investor sentiment regarding the strong uptake of Alnylam's lead drug, Amvuttra, which was approved for polyneuropathy of hATTR amyloidosis and recently expanded to ATTR amyloidosis with cardiomyopathy [2] - Amvuttra generated $801.9 million in global sales, reflecting an 89% year-over-year growth, driven by new patient treatments and patients switching from Onpattro [2] Financial Expectations - Alnylam is expected to report quarterly earnings of $1.39 per share, indicating a year-over-year increase of 378%, with revenues projected at $989.3 million, up 97.5% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 46.4% higher in the last 30 days, suggesting a positive trend that typically leads to price appreciation [4] Industry Context - Alnylam operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Foghorn Therapeutics Inc. (FHTX), experienced a 5.6% decline in its stock price, closing at $5.43, despite a 22.1% return over the past month [4] - Foghorn Therapeutics' consensus EPS estimate has increased by 6.7% to -$0.27, representing a 12.9% change compared to the previous year [5]
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?